February 14, 2005 -- Against quiet, though positive, action in the broad market, biotech attained a solid return to kick off the new week. The Centient Biotech 200 tacked on 19.87 points to close at 3381.49, a rise of .59%, about twice the gain of broad market indexes. We look at the positive Phase III results, and probable drug approval, for Encysive, a company we have liked for some time, an “approvable” letter for Discovery Labs, a study showing that patients like Exact Sciences’ colorectal screening product (at least, they liked it better than the competition), a promising laboratory test for OXiGENE’s anti-angiogenesis drug, and the implications of GenVec’s drug that grows hair in pigs’ ears--will it help you hear better? More detail...
